27,322 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Capital Fund Management S.A.

Capital Fund Management S.A. bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 27,322 shares of the company's stock, valued at approximately $1,130,000. Capital Fund Management S.A. owned 0.06% of Mirum Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Jones Financial Companies Lllp boosted its holdings in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares during the period. Legato Capital Management LLC boosted its holdings in shares of Mirum Pharmaceuticals by 7.9% in the fourth quarter. Legato Capital Management LLC now owns 13,395 shares of the company's stock worth $554,000 after buying an additional 977 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Mirum Pharmaceuticals by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock valued at $421,000 after buying an additional 1,003 shares in the last quarter. Rhumbline Advisers lifted its position in Mirum Pharmaceuticals by 2.4% in the 4th quarter. Rhumbline Advisers now owns 53,113 shares of the company's stock worth $2,196,000 after buying an additional 1,236 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Mirum Pharmaceuticals by 1.9% during the 4th quarter. Swiss National Bank now owns 70,300 shares of the company's stock valued at $2,907,000 after buying an additional 1,300 shares during the last quarter.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock traded up $0.35 during trading hours on Friday, hitting $39.10. 429,075 shares of the company's stock traded hands, compared to its average volume of 523,007. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a fifty day simple moving average of $45.23 and a 200-day simple moving average of $43.96. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -19.36 and a beta of 1.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 3,177 shares of the firm's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total value of $152,241.84. Following the transaction, the chief operating officer now directly owns 29,588 shares in the company, valued at $1,417,856.96. This trade represents a 9.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Christopher Peetz sold 27,279 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the transaction, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This represents a 16.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 116,473 shares of company stock valued at $5,249,134. Company insiders own 22.87% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. HC Wainwright boosted their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.